Emergency Use Authorization (EUA) for hydroxychloroquine‘s use for COVID-19 was revoked by the FDA “after trials showed it was ineffective and the FDA got reports of heart problems caused by the drug.” [1, 2] EUA was granted on March 28,2020.
The clinical trials used “potentially lethal” doses of hydroxychloroquine in hospitalised patients, contrary to use by frontline doctors who use the drug early, in combination with zinc and in normal, lower doses. [3]
The heart arrhythmia problems were reported in a fraudulent paper published in The Lancet on May 22, 2020 which was retracted just 14 days later.